Dannielle Appelhans

President and Chief Executive Officer, Cour Pharmaceuticals Development Co., Inc.

Professional Overview
Dannielle Appelhans is a seasoned pharmaceutical and biotechnology executive with extensive experience in operations, technical strategy, and business leadership. She currently serves as the President and Chief Executive Officer of Cour Pharmaceuticals Development Co., Inc., where she oversees the company's strategic direction and drives innovation in the field of immune-modulating therapies. Appelhans is also a Board Member at Generation Bio, contributing her expertise to the company's gene therapy initiatives.

Experience Summary

Current Role
As President and CEO of Cour Pharmaceuticals, Appelhans is responsible for setting the company's strategic vision, leading cross-functional teams, and navigating the complex regulatory landscape. Under her leadership, Cour Pharmaceuticals has accelerated the development of its pipeline of cutting-edge immunotherapies, positioning the company as a key player in the biotechnology industry.

Career Progression
Appelhans' career trajectory demonstrates her versatility and leadership abilities in the pharmaceutical and biotech sectors. Prior to her current role, she served as the Chief Operating Officer at Cour Pharmaceuticals, where she optimized the company's operational efficiency and played a crucial role in the successful transition of leadership. She has also held senior positions at Rubius Therapeutics and Novartis Gene Therapies, where she spearheaded global supply chain strategies, manufacturing operations, and technical excellence initiatives.

Academic Background
Appelhans holds a Bachelor of Science degree in Chemical Engineering from the University of Illinois at Urbana-Champaign, where she graduated with distinction.

Areas of Expertise
Appelhans' expertise spans a broad range of areas, including operations management, supply chain optimization, technical strategy, and regulatory compliance. She is a recognized leader in the development and commercialization of advanced therapies, with a deep understanding of the challenges and opportunities in the biotechnology industry.

Professional Impact
Throughout her career, Appelhans has led the successful implementation of several high-impact projects, including the optimization of Novartis' global supply chain operations and the seamless integration of Rubius Therapeutics' manufacturing capabilities. Her strategic vision and operational excellence have consistently driven positive business outcomes and contributed to the advancement of innovative therapies.

Conclusion
With her extensive experience, technical expertise, and proven track record of success, Dannielle Appelhans is well-positioned to lead Cour Pharmaceuticals into the next phase of growth and solidify the company's position as a leader in the development of immune-modulating therapies. Her commitment to innovation and her ability to navigate the complex pharmaceutical landscape make her a valuable asset to both Cour Pharmaceuticals and the broader biotechnology industry.